Related Experiment Video
Updated: Jun 22, 2026

Isolation and Culture Expansion of Tumor-specific Endothelial Cells
Published on: October 14, 2015
Circulating endothelial cells as biomarkers for angiogenesis in tumor progression
Ines Martin-Padura1, Francesco Bertolini
1Division of Hematology-Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy. ines.martinpadura@ifom-ieo-campus.it
Abstract:
An increased number of circulating endothelial cells (CECs) and endothelial progenitor cells (CEPs) has been reported in cancer patients. CEPs are derived from the bone marrow and will, during angiogenesis, differentiate into endothelial cells. CECs are mature endothelial cells (ECs) released from the vessel intima during physiological endothelial turnover or as a result of tumor treatment. Preclinical studies have shown that during tumor progression, the amount of circulating CECs correlates with angiogenesis. Moreover, there is growing evidence suggesting that CECs and CEPs viability and kinetics correlate with the patient responses to anti-angiogenic therapies. Thus, circulating CECs and CEPs may act as surrogate markers to test putative therapeutic efficacy. Moreover measuring CECs and CEPs may be useful to assess effects of antiangiogenic therapy.
More Related Videos
14:14Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
08:46Strategic Endothelial Cell Tube Formation Assay: Comparing Extracellular Matrix and Growth Factor Reduced Extracellular Matrix
Published on: August 14, 2016
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
The Tumor Microenvironment